Transpek Inds.

Transpek Industry Limited reported a total revenue of ₹505.6 crores for the nine months of FY25, marking a 12% year-on-year growth. EBITDA for the period stood at ₹90.3 crores, a 7.6% increase YoY, excluding an exceptional loss of ₹6.9 crores from discarding obsolete equipment. The EBITDA margin was 17.9%, a 70 basis points reduction compared to 9M FY24, while Profit After Tax declined by 10.4% to ₹29.5 crores. Management acknowledged that the Indian and global chemical industry has faced multiple challenges, including soft demand in major global markets like China and Europe, and volatility in chemical prices.

The Polymer segment continued to be the largest revenue contributor, accounting for over 58% of the total. Specialty chemicals contributed 19%, and Pharma contributed 10%. Geographically, International Business was the primary driver, making up 86% of the revenue, with North America alone contributing over 62% of this international share. The remaining 14% of business came from the domestic market. The company emphasized that its performance should be assessed on an annual basis due to the nature of its business.

Transpek is actively developing new non-acid/alkyl chloride products, with three currently in advanced stages. One product is expected to begin commercial supplies around April or May, gradually ramping up. These new products are projected to generate an annual revenue of ₹150-200 crores within two years, with an estimated EBITDA margin of 20%. The company follows a cautious approach to capital expenditure, investing only when there is clear demand visibility, and leverages its R&D capabilities for in-house technology development.

The current capacity utilization stands at approximately 65%, providing significant headroom for growth without immediate large-scale greenfield investments. Management indicated that existing facilities can be converted and utilized for new products during their initial ramp-up phases. Future capacity expansion, whether within existing facilities or through new plants, will be considered once new products achieve a critical mass in terms of volume, likely in 1.5 to 2 years.

Transpek maintains a strong relationship with DuPont, with a 10-year contract whose renewal discussions are anticipated in 1-1.5 years. Management expects to sustain current supply volumes. DuPont's new product, Kevlar EXO, an upgraded version of Kevlar, is expected to enter large-scale commercial production by January 2026. This development is projected to lead to a slight increase in demand for Transpek's raw materials, as Kevlar EXO is expected to have a higher consumption per unit of production.

The company has initiated the process for NSE listing and is in the final stages of submitting additional documents, with completion expected by April end. Regarding inorganic growth, Transpek has evaluated several opportunities but has not proceeded due to high valuations or a lack of strategic fit with its core values and sustainability practices. The company remains committed to finding opportunities that offer meaningful value addition and align with its ethos.